Mesoblast

Mesoblast Days Payable Outstanding

The Days Payable Outstanding (DPO) of Mesoblast (MSB.AX) as of Oct 20, 2026 is 644.40. In the previous year, Days Payable Outstanding (DPO) was 1,357.69 — a change of -52.54% (lower).

Days Payable Outstanding

644.40

YoY

-52.54%

Last updated:

Days Payable Outstanding (DPO) of Mesoblast is 2026 644.40 . Days Payable Outstanding (DPO) of Mesoblast was 2025 1,357.69 . It decreases by -52.54% lower compared to the previous year.

The Mesoblast Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2019
63.41 USD
Jan 1, 2020
111.84 USD
Jan 1, 2021
83.44 USD
Jan 1, 2022
132.51 USD
Jan 1, 2023
133.88 USD
Jan 1, 2024
62.83 USD
Jan 1, 2025
1,357.69 USD
Jan 1, 2026
644.40 USD
The Mesoblast Days Payable Outstanding history
YEARDays Payable OutstandingYoY
644.40-52.54%
1,357.69+2,060.79%
62.83-53.07%
133.88+1.03%
132.51+58.81%
83.44-25.40%
111.84+76.37%
63.41-94.94%
1,253.84+90.07%
659.66+98.09%
333.02-23.17%
433.43+45.74%
297.39—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

Days Payable Outstanding (DPO) of Mesoblast is 644.40 in 2026.

Days Payable Outstanding (DPO) of Mesoblast changed from 1,357.69 to 644.40, representing a -52.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Mesoblast since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Mesoblast with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Mesoblast

All Key Metrics — Mesoblast